BioNTech SE (BNTX) Receivables (2018 - 2025)

BioNTech SE has disclosed Receivables across 8 years of filings, most recently posting -$73.3 million for Q4 2025.

• Receivables for Q4 2025 came in at -$73.3 million, down 104.69% year-over-year; the trailing twelve-month figure through Dec 2025 was -$73.3 million (down 104.69% YoY), and the FY2025 annual result was -$71.2 million, down 104.55% from the prior year.
• Receivables came in at -$73.3 million for Q4 2025 at BioNTech SE, down from $807.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $14.2 billion in Q1 2022 to a low of -$73.3 million in Q4 2025.
• The 5-year median for Receivables is $807.6 million (2025), against an average of $3.8 billion.
• Peak annual rise in Receivables reached 26824.21% in 2024, while the deepest fall reached 801.24% in 2024.
• BioNTech SE's Receivables stood at $14.2 billion in 2021, then tumbled by 48.53% to $7.3 billion in 2022, then sank by 99.92% to $5.8 million in 2023, then surged by 26824.21% to $1.6 billion in 2024, then slumped by 104.69% to -$73.3 million in 2025.
• The last three Receivables figures came in at -$73.3 million (Q4 2025), $807.6 million (Q3 2025), and -$37.4 million (Q2 2025), per Business Quant data.